Development and in vitro characterization of paclitaxel and docetaxel loaded into hydrophobically derivatized hyperbranched polyglycerols

International Journal of Pharmaceutics

Volumn 404, Issue 1-2, 2011, Pages 238-249

  Mugabe, C ^a   Liggins, R T ^b   Guan, D ^b   Manisali, I ^b   Chafeeva, I ^a   Brooks, D E ^a   Heller, M ^b   Jackson, J K ^a   Burt, H M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Centre for Drug Research and Development   (Canada)

Author keywords

Cellular uptake; Cytotoxicity; Hydrophobically derivatized hyperbranched polyglycerols (HPGs); Purification; Stability; Taxanes

Indexed keywords

DOCETAXEL; GLYCEROL DERIVATIVE; NANOPARTICLE; OPAXIO; PACLITAXEL; PACLITAXEL POLIGLUMEX; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; DRUG UPTAKE; EVAPORATION; HUMAN; HUMAN CELL; NANOPHARMACEUTICS; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; GLYCEROL; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; KINETICS; MOLECULAR STRUCTURE; NANOTECHNOLOGY; PACLITAXEL; PARTICLE SIZE; POLYMERS; SOLUBILITY; TAXOIDS; TECHNOLOGY, PHARMACEUTICAL;

EID: 78650677292     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.11.010     Document Type: Article

References (64)

1. C. Allen, D. Maysinger, and A. Eisenberg Nano-engineering block copolymer aggregates for drug delivery Colloid Surf. B 16 1999 3 27
2. D. Bhadra, S. Bhadra, S. Jain, and N.K. Jain A PEGylated dendritic nanoparticulate carrier of fluorouracil Int. J. Pharm. 257 2003 111 124
3. E. Bilensoy, O. Gurkaynak, M. Ertan, M. Sen, and A.A. Hincal Development of nonsurfactant cyclodextrin nanoparticles loaded with anticancer drug paclitaxel J. Pharm. Sci. 97 2008 1519 1529
4. T. Brooks, and C.W. Keevil A simple artificial urine for the growth of urinary pathogens Lett. Appl. Microbiol. 24 1997 203 206
5. M. Calderon, M.A. Quadir, S.K. Sharma, and R. Haag Dendritic polyglycerols for biomedical applications Adv. Mater. 22 2010 190 218
6. M.G. Carstens, P.H. de Jong, C.F. van Nostrum, J. Kemmink, R. Verrijk, L.G. de Leede, D.J. Crommelin, and W.E. Hennink The effect of core composition in biodegradable oligomeric micelles as taxane formulations Eur. J. Pharm. Biopharm. 68 2008 596 606
7. J. Crown, and M. O'Leary The taxanes: an update Lancet 355 2000 1176 1178
8. J.F. Diaz, J.M. Valpuesta, P. Chacon, G. Diakun, and J.M. Andreu Changes in microtubule protofilament number induced by Taxol binding to an easily accessible site. Internal microtubule dynamics J. Biol. Chem. 273 1998 33803 33810
9. S.K. Dordunoo, and H.M. Burt Solubility and stability of taxol: effects of buffers and cyclodextrins Int. J. Pharm. 133 1996 191 201
10. S.K. Dordunoo, J.K. Jackson, L.A. Arsenault, A.M. Oktaba, W.L. Hunter, and H.M. Burt Taxol encapsulation in poly(epsilon-caprolactone) microspheres Cancer Chemother. Pharmacol. 36 1995 279 282
11. W. Du, L. Hong, T. Yao, X. Yang, Q. He, B. Yang, and Y. Hu Synthesis and evaluation of water-soluble docetaxel prodrugs-docetaxel esters of malic acid Bioorg. Med. Chem. 15 2007 6323 6330
12. M.E. Fox, S. Guillaudeu, J.M. Frechet, K. Jerger, N. Macaraeg, and F.C. Szoka Synthesis and in vivo antitumor efficacy of PEGylated poly(l-lysine) dendrimer-camptothecin conjugates Mol. Pharm. 6 2009 1562 1572
13. G. Gaucher, R.H. Marchessault, and J.C. Leroux Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes J. Control. Release 143 2010 2 12
14. H. Gelderblom, J. Verweij, K. Nooter, and A. Sparreboom Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation Eur. J. Cancer 37 2001 1590 1598
15. U.S. Gogate, P.A. Schwartz, and S.N. Agharkar Effect of unpurified Cremophor EL on the solution stability of paclitaxel Pharm. Dev. Technol. 14 2009 1 8
16. D.S. Grant, T.L. Williams, M. Zahaczewsky, and A.P. Dicker Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere) Int. J. Cancer 104 2003 121 129
17. B.A. Hadaschik, H. Adomat, L. Fazli, Y. Fraet, R.J. Andersen, M.E. Gleave, and A.I. So Intravesical chemotherapy of high grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin Clin. Cancer Res. 14 2008 1510 1518
18. B.A. Hadaschik, M.G. ter Borg, J. Jackson, R.D. Sowery, A.I. So, H.M. Burt, and M.E. Gleave Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer BJU Int. 101 2008 1347 1355
19. L. He, G.A. Orr, and S.B. Horwitz Novel molecules that interact with microtubules and have functional activity similar to Taxol Drug Discov. Today 6 2001 1153 1164
20. W. Henni-Silhadi, M. Deyme, M.M. Boissonnade, M. Appel, D. Le Cerf, L. Picton, and V. Rosilio Enhancement of the solubility and efficacy of poorly water-soluble drugs by hydrophobically-modified polysaccharide derivatives Pharm. Res. 24 2007 2317 2326
21. R.S. Herbst, and F.R. Khuri Mode of action of docetaxel - a basis for combination with novel anticancer agents Cancer Treat Rev. 29 2003 407 415
22. S.N. Huang, M.A. Phelps, and P.W. Swaan Involvement of endocytic organelles in the subcellular trafficking and localization of riboflavin J. Pharmacol. Exp. Ther. 306 2003 681 687
23. K. Iwase, Y. Oyama, T. Tatsuishi, J.Y. Yamaguchi, Y. Nishimura, A. Kanada, M. Kobayashi, Y. Maemura, S. Ishida, and Y. Okano Cremophor EL augments the cytotoxicity of hydrogen peroxide in lymphocytes dissociated from rat thymus glands Toxicol. Lett. 154 2004 143 148
24. J.K. Jackson, J. Smith, K. Letchford, K.A. Babiuk, L. Machan, P. Signore, W.L. Hunter, K. Wang, and H.M. Burt Characterization of perivascular poly(lactic-co-glycolic acid) films containing paclitaxel Int. J. Pharma. 283 2004 97 109
25. R.K. Kainthan, and D.E. Brooks In vivo biological evaluation of high molecular weight hyperbranched polyglycerols Biomaterials 28 2007 4779 4787
26. R.K. Kainthan, and D.E. Brooks Unimolecular micelles based on hydrophobically derivatized hyperbranched polyglycerols: biodistribution studies Bioconjug. Chem. 19 2008 2231 2238
27. R.K. Kainthan, S.R. Hester, E. Levin, D.V. Devine, and D.E. Brooks In vitro biological evaluation of high molecular weight hyperbranched polyglycerols Biomaterials 28 2007 4581 4590
28. R.K. Kainthan, J. Janzen, J.N. Kizhakkedathu, D.V. Devine, and D.E. Brooks Hydrophobically derivatized hyperbranched polyglycerol as a human serum albumin substitute Biomaterials 29 2008 1693 1704
29. R.K. Kainthan, C. Mugabe, H.M. Burt, and D.E. Brooks Unimolecular micelles based on hydrophobically derivatized hyperbranched polyglycerols: ligand binding properties Biomacromolecules 9 2008 886 895
30. C. Kontoyianni, Z. Sideratou, T. Theodossiou, L.A. Tziveleka, D. Tsiourvas, and C.M. Paleos A novel micellar PEGylated hyperbranched polyester as a prospective drug delivery system for paclitaxel Macromol. Biosci. 8 2008 871 881
31. A. Kunzmann, B. Andersson, T. Thurnherr, H. Krug, A. Scheynius, and B. Fadeel Toxicology of engineered nanomaterials: Focus on biocompatibility, biodistribution and biodegradation Biochim. Biophys. Acta 2010 10.1016/j.bbagen.2010.04.007
32. H. Lee, B. Hoang, H. Fonge, R.M. Reilly, and C. Allen In vivo distribution of polymeric nanoparticles at the whole-body, tumor, and cellular levels Pharm. Res. 27 2010 2343 2355
33. K. Letchford, and H. Burt A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes Eur. J. Pharm. Biopharm. 65 2007 259 269
34. K. Letchford, R. Liggins, and H. Burt Solubilization of hydrophobic drugs by methoxy poly(ethylene glycol)-block-polycaprolactone diblock copolymer micelles: theoretical and experimental data and correlations J. Pharm. Sci. 97 2008 1179 1190
35. S.Y. Leung, J. Jackson, H. Miyake, H. Burt, and M.E. Gleave Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors Prostate 44 2000 156 163
36. C. Li, and S. Wallace Polymer-drug conjugates: recent development in clinical oncology Adv. Drug Deliv. Rev. 60 2008 886 898
37. R.T. Liggins, W.L. Hunter, and H.M. Burt Solid-state characterization of paclitaxel J. Pharm. Sci. 86 1997 1458 1463
38. C. Mugabe, B.A. Hadaschik, R.K. Kainthan, D.E. Brooks, A.I. So, M.E. Gleave, and H.M. Burt Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy BJU Int. 103 2009 978 986
39. B. Otova, R. Vaclavikova, V. Danielova, J. Holubova, M. Ehrlichova, S. Horsky, P. Soucek, P. Simek, and I. Gut Effects of paclitaxel, docetaxel and their combinations on subcutaneous lymphomas in inbred Sprague-Dawley/Cub rats Eur. J. Pharm. Sci. 29 2006 442 450
40. R. Pazdur, A.P. Kudelka, J.J. Kavanagh, P.R. Cohen, and M.N. Raber The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere) Cancer Treat. Rev. 19 1993 351 386
41. R. Qi, Y. Gao, Y. Tang, R.R. He, T.L. Liu, Y. He, S. Sun, B.Y. Li, Y.B. Li, and G. Liu PEG-conjugated PAMAM dendrimers mediate efficient intramuscular gene expression AAPS J. 11 2009 395 405
42. M. Ramaswamy, X. Zhang, H.M. Burt, and K.M. Wasan Human plasma distribution of free paclitaxel and paclitaxel associated with diblock copolymers J. Pharm. Sci. 86 1997 460 464
43. C. Rangel, H. Niell, A. Miller, and C. Cox Taxol and taxotere in bladder cancer: in vitro activity and urine stability Cancer Chemother. Pharmacol. 33 1994 460 464
44. R. Rosenberg, W. Devenney, S. Siegel, and N. Dan Anomalous release of hydrophilic drugs from poly(epsilon-caprolactone) matrices Mol. Pharm. 4 2007 943 948
45. R. Savic, L. Luo, A. Eisenberg, and D. Maysinger Micellar nanocontainers distribute to defined cytoplasmic organelles Science 300 2003 615 618
46. F.A. Sheikh, N.A. Barakat, M.A. Kanjwal, S. Aryal, M.S. Khil, and H.Y. Kim Novel self-assembled amphiphilic poly(epsilon-caprolactone)-grafted- poly(vinyl alcohol) nanoparticles: hydrophobic and hydrophilic drugs carrier nanoparticles J. Mater. Sci. Mater. Med. 20 2009 821 831
47. J.W. Singer Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane J. Control. Release 109 2005 120 126
48. A. Sparreboom, C.D. Scripture, V. Trieu, P.J. Williams, T. De, A. Yang, B. Beals, W.D. Figg, M. Hawkins, and N. Desai Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol) Clin. Cancer Res. 11 2005 4136 4143
49. S.E. Stiriba, H. Kautz, and H. Frey Hyperbranched molecular nanocapsules: comparison of the hyperbranched architecture with the perfect linear analogue J. Am. Chem. Soc. 124 2002 9698 9699
50. R.M. Straubinger, and S.V. Balasubramanian Preparation and characterization of taxane-containing liposomes Methods Enzymol. 391 2005 97 117
51. H. Stutz The glass temperature of dendritic polymers J. Polymer Sci. Part B: Polymer Phys. 33 1995 333 340
52. M. Tanaka, T. Obata, and T. Sasaki Evaluation of antitumour effects of docetaxel (Taxotere) on human gastric cancers in vitro and in vivo Eur. J. Cancer 32A 1996 226 230
53. A.J. ten Tije, J. Verweij, W.J. Loos, and A. Sparreboom Pharmacological effects of formulation vehicles: implications for cancer chemotherapy Clin. Pharmacokinet. 42 2003 665 685
54. J. Tian, and V.J. Stella Degradation of paclitaxel and related compounds in aqueous solutions I: epimerization J. Pharm. Sci. 97 2008 1224 1235
55. J. Tian, and V.J. Stella Degradation of paclitaxel and related compounds in aqueous solutions II: Nonepimerization degradation under neutral to basic pH conditions J. Pharm. Sci. 97 2008 3100 3108
56. J. Tian, and V.J. Stella Degradation of paclitaxel and related compounds in aqueous solutions III: degradation under acidic pH conditions and overall kinetics J. Pharm. Sci. 99 2010 1288 1298
57. H. Turk, A. Shukla, P.C. Alves Rodrigues, H. Rehage, and R. Haag Water-soluble dendritic core-shell-type architectures based on polyglycerol for solubilization of hydrophobic drugs Chemistry 13 2007 4187 4196
58. L.A. Tziveleka, C. Kontoyianni, Z. Sideratou, D. Tsiourvas, and C.M. Paleos Novel functional hyperbranched polyether polyols as prospective drug delivery systems Macromol. Biosci. 6 2006 161 169
59. J. Verweij, M. Clavel, and B. Chevalier Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind Ann. Oncol. 5 1994 495 505
60. D. Wilms, S.E. Stiriba, and H. Frey Hyperbranched polyglycerols: from the controlled synthesis of biocompatible polyether polyols to multipurpose applications Acc. Chem. Res. 43 2010 129 141
61. L. Zhang, A.F. Radovic-Moreno, F. Alexis, F.X. Gu, P.A. Basto, V. Bagalkot, S. Jon, R.S. Langer, and O.C. Farokhzad Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates ChemMedChem 2 2007 1268 1271
62. X. Zhang, H.M. Burt, D. Von Hoff, D. Dexter, G. Mangold, D. Degen, A.M. Oktaba, and W.L. Hunter An investigation of the antitumour activity and biodistribution of polymeric micellar paclitaxel Cancer Chemother. Pharmacol. 40 1997 81 86 (Pubitemid 27160966)
63. S. Zhu, M. Hong, G. Tang, L. Qian, J. Lin, Y. Jiang, and Y. Pei Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: the effects of PEGylation degree and drug conjugation style Biomaterials 31 2010 1360 1371
64. W. Zoli, A. Flamigni, G.L. Frassineti, P. Bajorko, F. De Paola, C. Milandri, D. Amadori, and A. Gasperi-Campani In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers Breast Cancer Res. Treat. 34 1995 63 69